Strategies and perspectives in treatment of respiratory infections.
Bronchopulmonary infections in CF have a number of special features. The pathophysiology is determined by consequences of the basic CF defect and interactions with host defence systems, leading to chronic inflammation induced by Staphylococci and subsequently Pseudomonas. This results in lung tissue damage, various complications and eventually respiratory insufficiency. Policy of treatment is to combat infectious exacerbations and lung tissue destruction as much as possible. Factors in optimal treatment such as strategies, indications for therapy and selection of antibiotics are discussed.
Neijens
H J
HJ
Department of Paediatrics, Sophia Children's Hospital, Rotterdam, The Netherlands.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001982:Bronchial Diseases / Q000188:drug therapy*; D003550:Cystic Fibrosis / Q000378:metabolism / Q000382:microbiology*; D006801:Humans; D011552:Pseudomonas Infections / Q000188:drug therapy*; D012008:Recurrence; D013203:Staphylococcal Infections / Q000188:drug therapy*
D000900:Anti-Bacterial Agents